Radiotherapy +/- androgen supression (castration therapy)

A clinical oncologist, not a urologist, will manage radiotherapy in the UK.

Radiotherapy uses targeted radiation to treat prostate cancer. It may be given as external beam radiotherapy or brachytherapy (implanted radioactivity). In some cases, hormone therapy is added to improve cancer control.

Radiotherapy may be suitable for localised or locally advanced prostate cancer and is often discussed alongside surgery.

1

What is it?

Radiotherapy is either delivered from outside the body (external beam) or implanted (brachytherapy) into the prostate, or a combination of both

Radiotherapy uses targeted radiation (energy) to treat prostate cancer.

It may be used for localised prostate cancer, locally advanced prostate cancer, or recurrent prostate cancer after previous treatment. It may be given on its own or combined with hormone therapy, depending on the cancer risk.

Radiotherapy does not remove the prostate. Instead, it aims to damage and kill cancer cells while limiting damage to nearby healthy tissue.

2

Who is it for?

Radiotherapy may suit men who:

Have localised or locally advanced prostate cancer
Do not want surgery
Are not ideal surgical candidates
Have cancer features where radiotherapy plus hormone therapy is recommended
Have recurrent disease after previous treatment

Suitability depends on PSA, MRI, biopsy grade, cancer stage, urinary symptoms, bowel history, prostate size, general health and patient preference.

3

Benefits

Radiotherapy avoids an operation to remove the prostate. It may be suitable for men who do not want surgery or who are not ideal surgical candidates.

It can be effective for prostate cancer when carefully planned and delivered.

Radiotherapy may also be combined with hormone therapy for higher-risk disease, which can improve cancer control in selected men.

4

Risks

Radiotherapy can affect the bladder, bowel and sexual function. Side effects may include urinary frequency, urgency, discomfort passing urine, bowel looseness, rectal urgency, rectal bleeding, fatigue and erectile dysfunction.

Some side effects occur during or soon after treatment. Others may develop months or years later.

PSA follow-up after radiotherapy is different from PSA follow-up after surgery because the prostate remains in place.

Surgery after radiotherapy, if needed later, can be more complex because of scarring and tissue changes.

Prostate size and urinary symptoms

Prostate size and existing urinary symptoms matter when considering radiotherapy.

Some men with prostate cancer also have lower urinary tract symptoms, often called LUTS. These may include:

Passing urine frequently
Getting up at night to pass urine
Urgency
Slow flow
Hesitancy
Straining
Incomplete emptying
Urinary retention

A large prostate or significant urinary symptoms can make radiotherapy planning more complicated. Radiotherapy can irritate the bladder and prostate, and in some men urinary symptoms may worsen during or after treatment.

This is one area where surgery can sometimes offer an advantage. Radical prostatectomy removes the prostate and may also treat obstruction from the prostate at the same time. In men with troublesome LUTS caused by prostate enlargement, surgery may improve the obstructive element because the prostate is removed.

Radiotherapy does not remove the prostate. If a man already has poor flow, retention, severe nocturia or significant bladder outlet obstruction, this needs careful assessment before treatment.

Channel TURP before radiotherapy

Some men with severe urinary obstruction may need a procedure called a channel TURP before radiotherapy.

A TURP involves removing tissue from the inside of the prostate to improve the urinary channel. A channel TURP is usually a more limited version, intended to improve flow or relieve obstruction rather than remove the whole prostate.

This may be considered if urinary symptoms are severe, if the patient is in retention, or if there is concern that radiotherapy could worsen obstruction.

However, TURP before or after radiotherapy can have risks, including bleeding, scarring, urinary leakage, bladder neck narrowing and healing problems. Timing matters. This should be planned carefully by the urology and oncology teams.

Bowel function

Bowel history is important before radiotherapy.

The rectum sits directly behind the prostate, so radiotherapy can affect bowel function. Men with pre-existing bowel conditions may need more detailed discussion before treatment.

Possible bowel side effects include:

Loose stools
Rectal urgency
Mucus
Bleeding
Discomfort
Frequency
Rare longer-term bowel problems

Modern radiotherapy planning aims to reduce dose to the rectum, but bowel side effects cannot be completely removed.

Rectal spacers insert gel between the rectum and prostate to try and avoid this problem but not everyone can have a spacer and it requires specialist input

Sexual function

Radiotherapy can affect erections and sexual function.

This may happen gradually rather than immediately. Some men notice erectile dysfunction months or years after treatment. The risk is higher if hormone therapy is also used.

Radiotherapy may also reduce ejaculation, change orgasm and affect fertility.

Baseline erectile function matters. Age, diabetes, vascular disease, smoking, medication and testosterone levels can all influence sexual recovery and long-term function.

5

Before treatment

Before radiotherapy, the team will review:

PSA
MRI
Biopsy results
Grade Group
Cancer stage
Prostate size
Urinary symptoms
Flow rate and bladder emptying if needed
Bowel history
Erectile function
General health

You may need additional imaging, such as CT, bone scan or PSMA PET, depending on the cancer risk.

Radiotherapy usually involves detailed planning scans so the treatment can be targeted accurately. The oncology team will also decide whether the prostate alone, prostate plus seminal vesicles, or pelvic lymph node areas need treatment.

Hormone therapy may be recommended before, during or after radiotherapy depending on the cancer risk.

6

During treatment

There are several types of radiotherapy for prostate cancer.

External beam radiotherapy

External beam radiotherapy treats the prostate using radiation beams from outside the body.

Modern external beam radiotherapy is carefully planned using imaging. The aim is to deliver an effective dose to the prostate while reducing dose to the bladder, rectum and surrounding tissues.

Hypofractionated radiotherapy

Hypofractionation means giving a higher dose per treatment over fewer treatment sessions.

This can shorten the overall treatment course compared with older conventional schedules. It is commonly used in modern prostate radiotherapy pathways where appropriate.

Brachytherapy

Brachytherapy is internal radiotherapy. Radiation is delivered from inside the prostate or very close to it.

There are two main types:

Low-dose-rate brachytherapy
Tiny radioactive seeds are placed into the prostate. These slowly release radiation over time.

High-dose-rate brachytherapy
Temporary tubes or needles are placed into the prostate so a high dose of radiation can be delivered over a short period. The radioactive source is then removed.

Brachytherapy boost

In some higher-risk cases, brachytherapy may be used as a boost alongside external beam radiotherapy.

This means external beam radiotherapy treats the prostate and surrounding area, while brachytherapy gives an additional focused dose to the prostate itself.

Is ADT needed with radiotherapy?

Sometimes.

Hormone therapy, also called androgen deprivation therapy or ADT, lowers testosterone levels or blocks testosterone activity.

Testosterone can stimulate many prostate cancers, so reducing its effect can help control the disease.

ADT may be used with radiotherapy, after recurrence, or in advanced prostate cancer. It may be temporary or long-term depending on the situation.

Whether ADT is needed depends on cancer risk, Grade Group, PSA, MRI stage, lymph node risk and the radiotherapy plan.

Possible side effects of ADT

Side effects may include hot flushes, loss of libido, erectile dysfunction, fatigue, weight gain, loss of muscle, breast tenderness, mood changes, poor sleep, reduced concentration, bone thinning, increased diabetes risk and increased cardiovascular risk in some men.

Exercise, weight control, bone health monitoring and management of cardiovascular risk are important for men receiving longer-term hormone therapy.

 

7

After treatment

After radiotherapy, PSA is monitored over time.

Unlike surgery, the prostate remains in place, so PSA does not usually become undetectable. Instead, doctors look for the PSA to fall gradually and then remain stable.

Side effects may improve after treatment, but some men develop late urinary, bowel or sexual side effects months or years later.

Follow-up may involve the oncology team, urology team, GP and specialist nurses.

8

Has it worked?

Radiotherapy response is mainly monitored using PSA.

The PSA usually falls gradually over months and sometimes years. The lowest PSA reached is called the PSA nadir.

A later sustained rise in PSA may suggest recurrence and may lead to further tests such as MRI, CT, bone scan or PSMA PET depending on the situation.

9

Questions to ask

Am I suitable for radiotherapy?
Would I need external beam radiotherapy, brachytherapy, or both?
Is hypofractionated radiotherapy suitable for me?
Would brachytherapy boost be appropriate?
Do I need hormone therapy as well?
How long would ADT be needed?
Is my prostate size a problem for radiotherapy?
Could my urinary symptoms get worse?
Do I need a flow test or bladder scan before treatment?
Would I need a channel TURP before radiotherapy?
What are the bowel risks?
What is the risk to erectile function?
How will PSA be monitored afterwards?
What happens if the cancer comes back after radiotherapy?
Would surgery still be possible later?

11

Need further help?

Private consultations with Mr Anthony Bates are available through Prostatology for raised PSA, MRI review, biopsy results, prostate cancer treatment planning and second opinions.

Book through Prostatology:
https://www.prostatology.co.uk/consultations

©Copyright. All rights reserved.

Information icon

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.